The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis,…
HANGZHOU, China, Oct. 30, 2025 /PRNewswire/ — Jiuzi Holdings, Inc. (NASDAQ: JZXN) (“Jiuzi” or the “Company”), today detailed its SOLV Foundation partnership — a leading Bitcoin…
STOCKHOLM, Sweden, Oct. 30, 2025 /PRNewswire/ — Cerberus Capital Management, L.P. (“Cerberus”), a global alternative investment firm, today announced that…
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of…